Therapeutic strategies

[키워드] acute respiratory distress acute respiratory distress syndrome affected Antigen appear ARDS best C reactive protein cardiovascular comorbidities cardiovascular comorbidity CD19 cells characterized clinical Clinical symptoms clinical trial clinical trials Coagulopathy contribute convalescent plasma Corticosteroids cough COVID-19 COVID-19 patients Critical CRP Cytokine storm D-dimer disease drug therapy dysregulation Eosinopenia expression fatigue Fever focus helping hematological hematological parameter HLA-DR Host immune response human leukocyte antigen IL-6 IL-6 receptor immune immune dysregulation immune reactivity immune response Immunoglobulin immunological immunological reactivity immunosenescence Immunotherapy in-hospital mortality include Inflammatory response Intravenous immunoglobulin intubation IVIG Laboratory laboratory findings laboratory indexes. lead leukocyte Lymphocytes lymphopenia Macrophage macrophage activation syndrome Mild natural killer occur pathogenic mechanism pathogenic mechanisms Patient patients with COVID-19 predict procalcitonin prognostic biomarker Prognostic biomarkers Prognostic value receptor antagonist reduced reduction respiratory distress Respiratory distress syndrome SARS-CoV-2 severe COVID-19 severity severity of illness symptoms of COVID-19 syndrome T cell T cell response target Therapeutic strategies therapy Tocilizumab trajectory Treatment
[DOI] 10.1016/j.imlet.2021.01.001 PMC 바로가기 [Article Type] Review